Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

490 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular characterization of ESR1 variants in breast cancer.
Heeke AL, Elliott A, Feldman R, O'Connor HF, Pohlmann PR, Lynce F, Swain SM, Nunes MR, Magee D, Oberley MJ, Swenson J, Vidal G, Isaacs C, Schwartzberg L, Korn WM, Tan AR. Heeke AL, et al. Among authors: isaacs c. Breast Cancer Res Treat. 2022 Nov;196(2):279-289. doi: 10.1007/s10549-022-06740-y. Epub 2022 Sep 20. Breast Cancer Res Treat. 2022. PMID: 36125660
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ. Marcom PK, et al. Among authors: isaacs c. Breast Cancer Res Treat. 2007 Mar;102(1):43-9. doi: 10.1007/s10549-006-9307-8. Epub 2006 Aug 8. Breast Cancer Res Treat. 2007. PMID: 16897431 Clinical Trial.
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Isaacs C, Herbolsheimer P, Liu MC, Wilkinson M, Ottaviano Y, Chung GG, Warren R, Eng-Wong J, Cohen P, Smith KL, Creswell K, Novielli A, Slack R. Isaacs C, et al. Breast Cancer Res Treat. 2011 Jan;125(1):137-43. doi: 10.1007/s10549-010-1226-z. Epub 2010 Oct 26. Breast Cancer Res Treat. 2011. PMID: 20976541 Free PMC article. Clinical Trial.
BRCA1/2 mutations and triple negative breast cancers.
Peshkin BN, Alabek ML, Isaacs C. Peshkin BN, et al. Among authors: isaacs c. Breast Dis. 2010;32(1-2):25-33. doi: 10.3233/BD-2010-0306. Breast Dis. 2010. PMID: 21778580 Free PMC article. Review.
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA. Schwartzberg LS, et al. Among authors: isaacs c. Clin Cancer Res. 2013 May 15;19(10):2745-54. doi: 10.1158/1078-0432.CCR-12-3177. Epub 2013 Feb 26. Clin Cancer Res. 2013. PMID: 23444220 Clinical Trial.
490 results